Alizapride in prevention of postoperative nausea and vomiting.
A series of 90 ASA class 1 or 2 young adult female out-patients, randomly assigned to four groups, were treated with placebo (saline solution), alizapride 50 mg, alizapride 100 mg or alizapride 200 mg. The incidence of postoperative nausea and vomiting has been estimated. The incidence of nausea and vomiting was lower with the alizapride-treated patients, while, contrary to the experience with other antiemetics, prolonged recovery was not observed. The incidence of vomiting in the placebo-group was twice as high as in the alizapride-groups. Of the placebo-treated patients, 20 percent requested further antiemetic medication within four hours while none of the alizapride-treated patients needed this. Alizapride 100 to 200 mg intravenously is efficacious in the prevention of postoperative nausea and vomiting.
Booij
L H
LH
Department of Anaesthesiology, Free University Hospital, Amsterdam, The Netherlands.
Rachmat
S
S
Bulder
E R
ER
D000768:Anesthesia, General / Q000009:adverse effects*; D000932:Antiemetics; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D009325:Nausea / Q000517:prevention & control*; D010919:Placebos; D011759:Pyrrolidines / Q000627:therapeutic use*; D014839:Vomiting / Q000517:prevention & control*
D000932:Antiemetics; D010919:Placebos; D011759:Pyrrolidines; C033968:alizapride